ArticleRespiratory research2026
Serum metabolomic profiles linking diabetes mellitus to pulmonary hypertension: a prospective cohort study with mediation analysis and risk prediction.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMetabolic dysregulation in patients with diabetes mellitus (DM) may contribute to pulmonary vascular remodeling, yet biomarkers for pulmonary hypertension (PH) risk in diabetes remain unclear.
objectivesTo assess the association between DM and incident PH, quantify mediation by circulating metabolites, and develop a metabolite-based PH risk model in diabetes.
methodsIn a prospective cohort of 459,714 UK Biobank participants without PH at baseline, Cox proportional hazard models estimated the association between DM and incident PH. Nuclear magnetic resonance (NMR) metabolomics, mediation analysis, and LASSO regression were used to identify metabolic mediators and construct a predictive model.
resultsDuring a median follow-up of 13.25 years, 2,250 PH cases occurred. DM was associated with a 39.6% higher PH risk (HR = 1.396, 95%CI:1.255–1.553; P < 0.001), and earlier DM onset was associated with stronger risk (P < 0.001). Seven NMR-derived metabolites—related to hyperglycemia, inflammation (glycoprotein acetyls), amino acid and lipid metabolism—mediated 37.26% of the total effect. Including these metabolites improved prediction in diabetes (C index from 0.692 to 0.735; P < 0.001).
conclusionsDM is an independent risk factor for PH. Integration of NMR-derived metabolites improves risk prediction and suggests hyperglycemia and inflammation as key mechanisms, supporting the role of metabolomics in PH stratification and prevention among diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.